AURKA and diffuse large B-cell lymphoma: The integration of an AURKA inhibitor in conjunction with chidamide constitutes a novel and potentially effective therapeutic approach for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [83].